S&P 500
7,757.17
+44.60
+0.58%
Dow
52,856.09
+360.19
+0.69%
Nasdaq
26,702.86
+278.04
+1.05%
NYSE Composite
24,253.12
+62.52
+0.26%
Russell 2000
2,781.02
+7.60
+0.27%
VIX
16.68
-0.63
-3.64%
VRCA · Verrica Pharmaceuticals Inc.
NASDAQ NMS - GLOBAL MARKET - BOATS Real Time Price • USD
Verrica Pharmaceuticals Inc (VRCA)
NASDAQ NMS - GLOBAL MARKET
Pharmaceuticals
$3.62
+0.30
(+9.04%)
● At close: October 21 at 4:00:00 PM EDT
DAY'S RANGE
$3.62
$3.50
$3.64
52-WEEK RANGE
$3.62
$3.28
$9.82
What's happening
- VRCA is up 9.04% today, trading at $3.62. — Live quote
- Volume today (4,974) is well below its 3-month average of 60,090. (Finnhub fundamentals)
- Reports earnings on 2026-11-09, 18 days away. (Finnhub earnings calendar)
- Last quarter's EPS missed estimates: $-0.54 actual vs. $-0.43 estimated (-25.5%). (Finnhub earnings history)
Deterministic template sentences filled in from the same sourced figures shown elsewhere on this page -- not an AI-written summary, no live model call.
Key Statistics
Analyst Recommendations
Strong buy 3
Buy 8
Hold 2
Sell 0
Strong sell 0
Aggregate ratings for 2026-10-01 (13 analysts polled by Finnhub) — consensus count.
Performance Overview (Trailing returns vs S&P 500 benchmark)
YTD RETURN
VRCA
-58.24%
vs S&P 500
-71.02%
1-YEAR RETURN
VRCA
-22.54%
vs S&P 500
-37.11%
6-MONTH RETURN
VRCA
-44.12%
3-MONTH RETURN
VRCA
-36.21%
Earnings Trends (Quarterly EPS Actual vs Estimate)
2026-07-26 (Q2 2026)
$-0.54
Est. $-0.43
MISS -25.5%
2026-04-26 (Q1 2026)
$-0.41
Est. $-0.46
BEAT +11.4%
2026-01-26 (Q4 2025)
$-0.46
Est. $-0.81
BEAT +43.2%
2025-10-26 (Q3 2025)
$-0.03
Est. $-0.69
BEAT +95.6%
Valuation Measures & Ratios
Enterprise Value4$51.4M
Forward P/E5—
PEG Ratio6—
Price / Sales (TTM1)2.02
Price / Book724.41
EV4 / Revenue1.70
EV4 / EBITDA—
Profit Margin-102.84%
Operating Margin-98.64%
Return on Equity (ROE8)-205.58%
Return on Assets (ROA9)-76.60%
Avg Volume (3M)60,090
Quarterly history (5 periods)
| Measure | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 |
|---|---|---|---|---|---|
| Market cap | $130.4M | $112.7M | $38.9M | $54.1M | $41.6M |
| P/E | -5.69 | -5.78 | -1.19 | -1.09 | -0.59 |
| Price/Sales | 3.44 | 3.18 | 1.36 | — | — |
| Price/Book | 30.27 | 7.02 | -2.28 | -3.09 | -2.24 |
| EV/Revenue | 3.14 | 2.59 | 1.81 | — | — |
| ROE | -531.81% | -121.42% | 191.74% | 283.60% | 377.47% |
| ROA | -63.59% | -50.26% | -79.89% | -126.79% | -166.25% |
Trailing-twelve-month ratios computed from SEC EDGAR quarterly figures and historical daily close prices (Alpaca). Diluted shares are derived from Net income ÷ EPS (diluted) for each quarter, not separately reported. Forward P/E/PEG unavailable (no free data source).
Glossary — what these abbreviations mean
- 1. TTM
- Trailing twelve months — the sum of the last four reported quarters, not a calendar year or the single latest quarter.
- 2. EPS
- Earnings per share — net income divided by diluted shares outstanding.
- 3. Beta
- A stock's historical volatility relative to the overall market. Above 1 means it has moved more than the market; below 1, less.
- 4. EV (Enterprise Value)
- Market cap plus total debt minus cash — roughly what it would cost to buy the whole company, debt included.
- 5. Forward P/E
- Price divided by analysts' estimated earnings for the next 12 months, instead of trailing actual earnings.
- 6. PEG Ratio
- P/E divided by expected earnings growth rate. A lower number can indicate a stock is cheap relative to how fast it's expected to grow.
- 7. Price / Book
- Share price divided by book value (assets minus liabilities) per share.
- 8. ROE
- Return on equity — net income divided by shareholders' equity, a measure of how efficiently a company turns equity into profit.
- 9. ROA
- Return on assets — net income divided by total assets, a measure of how efficiently a company turns assets into profit.
- 10. MRQ
- Most recent quarter — the single latest reported period, as opposed to TTM. The Financials section's "Quarterly" view below shows MRQ-style figures.
- 11. YoY
- Year over year — percent change versus the same period one year earlier, used for growth figures like those on Compare cards and the Screener.
Short Interest
Shares Short196,221
Change from Prior Settlement-3.22%
% of Float—
Days to Cover (Short Ratio)4.06
Source: FINRA Rule 4560 consolidated short interest, settlement date 2026-09-30. Reported bi-monthly with a reporting lag — not real-time.
Quotes and the 1-day extended-hours chart: Yahoo Finance. Longer historical charts: Alpaca (IEX feed) — real-time but IEX-only volume (~2.5% of consolidated market volume). Fundamentals + earnings: Finnhub.
Price history
Events
Drag horizontally to zoom into a section; use Reset view to restore all observations.
Technical signal summary
Calculating from the latest year of daily price history…
Show Technical Analysis Breakdown ▾ 10 Indicators
Not investment advice — read several signals together.
Indicators None active
Loading chart…
History limited by data provider; markers are heuristics, not signals.
Peer and sector context
No reviewed peer group is available for this symbol.
Balanced evidence
A deterministic summary of sourced facts—not an AI verdict.
Potential strengths
- Latest SEC filing is Form 4, filed 2026-08-18; review it for current changes and risks. SEC EDGAR ↗
Potential concerns
- Revenue growth is -53.9% on the provider's reported measure. Finnhub fundamentals ↗
- Net profit margin is -102.8%. Finnhub fundamentals ↗
- Trailing 52-week price return is -22.5%. Finnhub market metrics ↗
Rule-based facts only; absence from either side is not evidence, and this is not a recommendation.
More on VRCA
No accessible free API for these — links go to the source directly.
Financials
Fundamental trends
Visualized from the same SEC figures in the tables below.
Income statement
| Line item | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 | Sep '24 | Jun '24 | Mar '24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $5.9M | $5.0M | $14.3M | $12.7M | $3.4M | -$1.8M | — | — |
| Operating income | -$13.1M | -$9.7M | $1.6M | $1.5M | -$8.1M | -$20.7M | -$15.2M | -$18.6M |
| Net income | -$13.2M | -$9.7M | -$274.0K | $204.0K | -$9.7M | -$22.9M | -$17.2M | -$20.3M |
| EPS (diluted) | $-0.62 | $-0.45 | $-0.03 | $0.02 | $-1.03 | $-4.88 | $-3.70 | $-0.44 |
| EPS (basic) | $-0.62 | $-0.45 | $-0.03 | $0.02 | $-1.03 | $-4.88 | $-3.70 | $-0.44 |
| Operating margin | -$223 | -$193 | $11 | $12 | -$236 | $1.2K | — | — |
| Net margin | -$224 | -$193 | -$2 | $2 | -$283 | $1.3K | — | — |
Balance sheet
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Total assets | $36.0M | $38.8M | $47.1M | $40.9M | $39.1M | $42.2M | $54.1M | $32.9M |
| Total liabilities | $31.7M | $22.7M | $22.4M | $57.9M | $56.6M | $60.8M | $64.0M | $67.0M |
| Stockholders' equity | $4.3M | $16.1M | $24.7M | -$17.0M | -$17.5M | -$18.6M | -$9.9M | -$34.1M |
| Total current assets | $32.6M | $34.1M | $42.5M | $36.3M | $36.8M | $39.5M | $51.2M | $28.2M |
| Total current liabilities | $22.4M | $16.2M | $16.4M | $28.9M | $29.2M | $29.4M | $29.0M | $21.0M |
| Cash & equivalents | $11.2M | $20.6M | $30.1M | $21.1M | $15.4M | $29.6M | $46.3M | $23.0M |
| Accounts receivable | $10.9M | $7.7M | $5.3M | $7.0M | $9.2M | $5.6M | $48.0K | $0 |
| Inventory | $2.7M | $2.0M | $2.2M | $2.3M | $2.5M | $2.5M | $2.5M | $2.6M |
| Property, plant & equipment | $177.0K | $191.0K | $209.0K | $225.0K | $315.0K | $537.0K | $589.0K | $651.0K |
| Other non-current assets | $638.0K | $640.0K | $376.0K | $376.0K | $376.0K | $376.0K | $376.0K | $538.0K |
| Accounts payable | $1.6M | $2.2M | $2.1M | $1.6M | $2.3M | $1.4M | $1.9M | $966.0K |
| Accrued liabilities | — | — | — | — | — | — | — | — |
| Deferred revenue (current) | $1.3M | $1.0M | $782.0K | $1.6M | — | — | $0 | — |
| Short-term debt | — | — | $0 | $12.5M | $12.7M | $12.8M | $12.9M | — |
| Other current liabilities | $180.0K | $200.0K | $119.0K | $59.0K | $366.0K | $166.0K | $105.0K | $428.0K |
| Long-term debt | — | — | $0 | $21.6M | $24.6M | $27.8M | $31.0M | $43.3M |
| Other non-current liabilities | — | — | — | — | — | — | — | — |
| Common stock & paid-in capital | $2.0K | $2.0K | $2.0K | $1.0K | $1.0K | $9.0K | $1.0K | $5.0K |
| Retained earnings | -$347.7M | -$334.6M | -$324.9M | -$316.8M | -$316.6M | -$316.8M | -$307.0M | -$290.8M |
| Accumulated other comprehensive income (loss) | — | — | — | — | — | — | — | — |
Cash flow
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$9.3M | -$9.2M | -$4.6M | $9.7M | -$10.0M | -$12.7M | -$16.1M | -$8.6M |
| Investing cash flow | $0 | $0 | $0 | $0 | $0 | $0 | $8.0K | -$16.0K |
| Financing cash flow | -$126.0K | -$120.0K | $13.6M | -$4.0M | -$4.2M | -$4.1M | $39.4M | -$397.0K |
| Free cash flow | — | — | -$4.6M | $9.7M | -$10.0M | — | -$16.1M | -$8.6M |
| Capital expenditures | — | — | $0 | $0 | $0 | — | $0 | $16.0K |
| Deferred income taxes | — | — | — | — | — | — | — | — |
| Change in accounts receivable | $3.2M | $2.5M | -$1.8M | -$2.1M | $3.6M | $5.6M | $201.0K | -$10.2M |
| Change in inventory | $738.0K | -$262.0K | — | -$218.0K | $59.0K | $0 | — | $0 |
| Change in accounts payable | -$590.0K | $121.0K | $487.0K | -$736.0K | $878.0K | -$453.0K | $931.0K | -$169.0K |
| Purchases of investments | — | — | — | — | — | — | — | — |
Income statement
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Revenue | $35.6M | $7.6M | — | — | — |
| Operating income | -$12.2M | -$65.9M | -$65.8M | -$21.3M | -$30.9M |
| Net income | -$17.9M | -$76.6M | -$67.0M | -$24.5M | -$35.1M |
| EPS (diluted) | $-1.68 | $-14.78 | $-1.48 | $-0.72 | $-1.30 |
| EPS (basic) | $-1.68 | $-14.78 | $-1.48 | $-0.72 | $-1.30 |
| Operating margin | -$34 | -$871 | — | — | — |
| Net margin | -$50 | -$1.0K | — | — | — |
Balance sheet
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Total assets | $47.1M | $54.1M | $81.6M | $44.7M | $80.1M |
| Total liabilities | $22.4M | $64.0M | $61.8M | $4.7M | $47.5M |
| Stockholders' equity | $24.7M | -$9.9M | $19.8M | $40.0M | $32.6M |
| Total current assets | $42.5M | $51.2M | $77.5M | $39.1M | $74.3M |
| Total current liabilities | $16.4M | $29.0M | $17.0M | $3.5M | $46.1M |
| Cash & equivalents | $30.1M | $46.3M | $69.5M | $34.3M | $15.8M |
| Accounts receivable | $5.3M | $48.0K | $4.2M | $0 | — |
| Inventory | $2.2M | $2.5M | $1.0M | $0 | — |
| Property, plant & equipment | $209.0K | $589.0K | $1.1M | $3.9M | $3.9M |
| Other non-current assets | $376.0K | $376.0K | $452.0K | $276.0K | $295.0K |
| Accounts payable | $2.1M | $1.9M | $2.5M | $507.0K | $845.0K |
| Accrued liabilities | — | — | — | — | — |
| Deferred revenue (current) | $782.0K | $0 | — | — | — |
| Short-term debt | $0 | $12.9M | $0 | — | — |
| Other current liabilities | $119.0K | $105.0K | $244.0K | $0 | — |
| Long-term debt | $0 | $31.0M | $42.9M | $0 | — |
| Common stock & paid-in capital | $2.0K | $1.0K | $4.0K | $4.0K | $3.0K |
| Retained earnings | -$324.9M | -$307.0M | -$230.4M | -$163.5M | -$139.0M |
| Accumulated other comprehensive income (loss) | — | — | — | $0 | -$29.0K |
Cash flow
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Operating cash flow | -$17.6M | -$60.9M | -$38.6M | -$18.6M | -$27.6M |
| Investing cash flow | $0 | -$19.0K | -$362.0K | $54.0M | -$998.0K |
| Financing cash flow | $1.4M | $37.7M | $74.2M | -$16.9M | $33.6M |
| Free cash flow | -$17.6M | -$61.0M | -$38.9M | -$19.0M | -$28.5M |
| Capital expenditures | $0 | $27.0K | $362.0K | $302.0K | $883.0K |
| Deferred income taxes | — | — | — | — | -$2.4M |
| Change in accounts receivable | $5.2M | -$4.2M | $3.9M | $0 | — |
| Change in accounts payable | $176.0K | -$568.0K | $2.2M | -$338.0K | $497.0K |
| Purchases of investments | — | — | $0 | $4.5M | $68.9M |
Source: SEC EDGAR XBRL filings (10-Q/10-K), as originally tagged by the company. Quarterly cash flow is reconstructed by de-cumulating fiscal-year-to-date figures (how cash flow is tagged in 10-Qs); other quarterly lines are reported directly.
Institutional holders
SEC Form 13F filers holding VRCA as of the latest reported quarter. 13F only covers investment managers with $100M+ in assets — this is not a complete ownership picture, and does not include insiders (see Recent SEC filings below) or non-13F-eligible holders.
Institutional ownership is not available for this symbol right now.
Insider activity
Directors, officers, and 10%+ owners' reported transactions from SEC Form 4. A filing reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR Form 4 filings · checked 25 most recent filings · covers 2025-03-17 to 2026-08-18
Recent transactions
- Insiders have net bought 42,230 shares over the last 182 days, across 6 purchases and 0 sales.
- Most recent: Rosenberg Noah L. (CMO) — Open market purchase of 2,030 shares on 2026-08-18.
Deterministic template sentences filled in from the SEC Form 4 figures in the tables below -- not an AI-written summary, no live model call.
Insider purchases & sales, last 6 months
Purchases (open market)42,230 sh(6 txns)
Sales (open market)0 sh(0 txns)
Net Shares+42,230
Counts only open-market purchases (code P) and sales (code S) — grants, option exercises, tax withholding, and gifts are excluded since they aren't a market buy/sell decision.
Insider roster
| Name | Title | Most Recent Transaction | Date | Shares |
|---|---|---|---|---|
| Rosenberg Noah L. | CMO | Open market purchase | 2026-08-18 | 2,030 |
| Kirby John J. | Interim CFO | Open market purchase | 2026-08-18 | 5,000 |
| Zawitz David | Chief Operating Officer | Open market purchase | 2026-08-17 | 6,000 |
| Rieger Jayson | CEO and President | Open market purchase | 2026-08-17 | 5,000 |
| Manning Paul B | Reporting person | Open market purchase | 2025-11-25 | 1,375,380 |
| Hayes Christopher G. | CHIEF LEGAL OFFICER | Open market sale | 2025-03-17 | 4,315 |
Recent transactions
| Date | Insider | Title | Transaction | Shares | Price |
|---|---|---|---|---|---|
| 2026-08-18 | Rosenberg Noah L. | CMO | Open market purchase | 2,030 | $4.92 |
| 2026-08-18 | Kirby John J. | Interim CFO | Open market purchase | 5,000 | $4.93 |
| 2026-08-17 | Zawitz David | Chief Operating Officer | Open market purchase | 6,000 | $4.98 |
| 2026-08-17 | Rieger Jayson | CEO and President | Open market purchase | 5,000 | $4.91 |
| 2026-08-17 | Rosenberg Noah L. | CMO | Open market purchase | 4,200 | $4.91 |
| 2026-08-14 | Rieger Jayson | CEO and President | Open market purchase | 20,000 | $5.06 |
| 2025-12-23 | Kirby John J. | Interim CFO | Grant / award | 10,000 | $0.00 |
| 2025-11-25 | Rosenberg Noah L. | CMO | Open market purchase | 2,357 | $4.24 |
| 2025-11-25 | Kirby John J. | Interim CFO | Open market purchase | 3,536 | $4.24 |
| 2025-11-25 | Zawitz David | Chief Operating Officer | Open market purchase | 10,000 | $4.24 |
| 2025-11-25 | Rieger Jayson | CEO and President | Open market purchase | 94,311 | $4.24 |
| 2025-11-25 | Manning Paul B | Reporting person | Open market purchase | 1,375,380 | $4.24 |
| 2025-11-25 | Manning Paul B | Reporting person | Open market purchase | 2,750,762 | $4.24 |
| 2025-03-17 | Hayes Christopher G. | CHIEF LEGAL OFFICER | Open market sale | 4,315 | $0.65 |
Recent SEC filings
Official company reports and insider transaction filings. Form 4 reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR submissions · updated 2026-10-22 07:06 UTC
| Filed | Form | Report period | Official filing |
|---|---|---|---|
| 2026-08-18 | 4 | 2026-08-17 | View on SEC.gov → |
| 2026-08-18 | 4 | 2026-08-14 | View on SEC.gov → |
| 2026-08-18 | 4 | 2026-08-17 | View on SEC.gov → |
| 2026-08-18 | 4 | 2026-08-18 | View on SEC.gov → |
| 2026-08-06 | 10-Q | 2026-06-30 | View on SEC.gov → |
| 2026-08-06 | 8-K | 2026-08-06 | View on SEC.gov → |
| 2026-06-09 | 4 | 2026-06-05 | View on SEC.gov → |
| 2026-06-09 | 4 | 2026-06-05 | View on SEC.gov → |
| 2026-06-09 | 4 | 2026-06-05 | View on SEC.gov → |
| 2026-06-09 | 4 | 2026-06-05 | View on SEC.gov → |
| 2026-06-09 | 4 | 2026-06-05 | View on SEC.gov → |
| 2026-06-09 | 4 | 2026-06-05 | View on SEC.gov → |
Recent news
Headlines about VRCA (Verrica Pharmaceuticals Inc.). Links open the publisher — we don’t host full articles.
-
CDNL,ANGX,OTLK,CUEN,LIEN,STRR,FISV,SPG,FRST,ACCS,GRNT,MTDR,BGDE,ACON,CC,BCDA,MLCI,MSIF,RSG,SELF,CWBC,PSNY,VRCA,RVSB,AWRE | Stock Prices | Quote Comparison
Yahoo! Finance Canada · 2026-10-21 -
ANGX,CDNL,OTLK,CUEN,LIEN,STRR,FISV,PRTA,SPG,ACCS,VIRC,FRST,GRNT,MTDR,BGDE,ACON,CC,BCDA,MSIF,SELF,PSNY,VRCA,AWRE,SMRT,APCX | Stock Prices | Quote Comparison
Yahoo! Finance Canada · 2026-10-21 -
VRCA Oct 2026 5.000 put (VRCA261016P00005000) interactive stock chart
Yahoo Finance UK · 2026-10-20 -
Verrica reports USD 5.86 million revenue. Target for Verrica Pharmaceuticals stock is USD 12.67
AD HOC NEWS · 2026-10-20 -
CDNL,ANGX,OTLK,CUEN,LIEN,FISV,STRR,SPG,FRST,ACCS,GRNT,MTDR,BGDE,ACON,CC,BCDA,MLCI,MSIF,RSG,CWBC,SELF,PSNY,VRCA,RVSB,AWRE | Stock Prices | Quote Comparison
Yahoo! Finance Canada · 2026-10-18 -
Lake Street sets USD 9.00 target for Verrica Pharmaceuticals stock - ad-hoc-news.de
ad-hoc-news.de · 2026-10-18 -
Lake Street keeps Buy rating for Verrica Pharmaceuticals stock - ad-hoc-news.de
ad-hoc-news.de · 2026-10-15 -
VRCA Nov 2026 5.000 call (VRCA261120C00005000) Stock Price, News, Quote & History
Yahoo! Finance Canada · 2026-10-15
No headlines in this category right now — try “All”.